(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
WE CLOSED MYND ANALYTICS AT $2.45 FOR A 76% GAIN!
Featured in the current Newsletter is a maker of surgical products for people with back issues that is trading at around $2.95; and a biotech that is developing therapies that are aimed at children's illnesses and is trading at around $1.15 and is a CHANNELED PICK. Read about our PROVEN CHANNELING STRATEGY above!
In the next Newsletter, coming soon, are two more biotech picks. One has been rated a BUY FROM SIX ANALYSTS and has a $12 million grant from BARDA to develop one of its lead drug candidates. The other pick is rated a BUY FROM FOUR ANALYSTS and has collaborations with several pharma's and is A CHANNELED STOCK PICK! Read about our Proven Channeling Strategy above!.
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)